Literature DB >> 2313769

Depressive symptoms during buprenorphine treatment of opioid abusers.

T R Kosten1, C Morgan, T A Kosten.   

Abstract

Among 40 opioid addicts treated as outpatients with sublingual buprenorphine (2-8 mg daily) for a month, depressive symptoms significantly decreased in the 19 who were depressed at intake to treatment.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2313769     DOI： 10.1016/0740-5472(90)90035-o

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN： 0740-5472


  27 in total

1.  Is residential treatment effective for opioid use disorders? A longitudinal comparison of treatment outcomes among opioid dependent, opioid misusing, and non-opioid using emerging adults with substance use disorder.

Authors:  Zev Schuman-Olivier; M Claire Greene; Brandon G Bergman; John F Kelly
Journal:  Drug Alcohol Depend       Date:  2014-09-18       Impact factor: 4.492

2.  Opioidergic Agents as Antidepressants: Rationale and Promise.

Authors:  Parnika P Saxena; J Alexander Bodkin
Journal:  CNS Drugs       Date:  2019-01       Impact factor: 5.749

3.  Antidepressant treatment does not improve buprenorphine retention among opioid-dependent persons.

Authors:  Michael D Stein; Debra S Herman; Malyna Kettavong; Patricia A Cioe; Peter D Friedmann; Tahir Tellioglu; Bradley J Anderson
Journal:  J Subst Abuse Treat       Date:  2010-07-03

Review 4.  Investigational drugs in recent clinical trials for treatment-resistant depression.

Authors:  Ricardo P Garay; Carlos A Zarate; Thomas Charpeaud; Leslie Citrome; Christoph U Correll; Ahcène Hameg; Pierre-Michel Llorca
Journal:  Expert Rev Neurother       Date:  2017-01-29       Impact factor: 4.618

5.  Self-reported Sleep Improvement in Buprenorphine MAT (Medication Assisted Treatment) Population.

Authors:  W H Zheng; R J Wakim; R C Geary; L R Lander; S J Wen; M C Xiao; C R Sullivan
Journal:  Austin J Drug Abuse Addict       Date:  2016-07-25

6.  Predictors of Daily Pain Medication Use in Individuals with Recurrent Back Pain.

Authors:  John A Sturgeon; Jennifer M Hah; Yasamin Sharifzadeh; Stephanie K Middleton; Thomas Rico; Kevin A Johnson; Sean C Mackey
Journal:  Int J Behav Med       Date:  2018-04

Review 7.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

Review 8.  Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials.

Authors:  William A Carlezon; Andrew D Krystal
Journal:  Depress Anxiety       Date:  2016-10       Impact factor: 6.505

9.  Self-loathing aspects of depression reduce postoperative opioid cessation rate.

Authors:  Jennifer M Hah; Sean Mackey; Peter L Barelka; Charlie K M Wang; Bing M Wang; Matthew J Gillespie; Rebecca McCue; Jarred W Younger; Jodie Trafton; Keith Humphreys; Stuart B Goodman; Fredrick M Dirbas; Peter C Schmidt; Ian R Carroll
Journal:  Pain Med       Date:  2014-06       Impact factor: 3.750

10.  Effects of buprenorphine on behavioral tests for antidepressant and anxiolytic drugs in mice.

Authors:  Edgardo Falcon; Kaitlyn Maier; Shivon A Robinson; Tiffany E Hill-Smith; Irwin Lucki
Journal:  Psychopharmacology (Berl)       Date:  2014-09-03       Impact factor: 4.530
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.